Shuang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuang Wang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Fan Deng
Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
4 shared publications Jingyi Chen
Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Anesthesiology Research Institute of Hubei University of Medicine, Shiyan, Hubei Province, China
4 shared publicationsWenqian Yu
Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Anesthesiology Research Institute of Hubei University of Medicine, Shiyan, Hubei Province, China
4 shared publicationsDong-Mei Jiang
2 shared publicationsFan Deng
Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
2 shared publications- Hui-Juan Jiang
Department of Hematology Tianjin Medical University General Hospital Tianjin China
2 shared publications
Latest Publications
- Open Access
- 1 January 2022
- Published by Elsevier in Molecular Therapy
- Vol. 30 (1) , 501
Long Noncoding RNA-Maternally Expressed Gene 3 Contributes to Hypoxic Pulmonary Hypertension
- 1 January 2022
- Published by Elsevier in Molecular Therapy
- Vol. 30 (1) , 501
Open AccessLong Noncoding RNA-Maternally Expressed Gene 3 Contributes to Hypoxic Pulmonary Hypertension
- 1 May 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 283, 151
MALAT1/miR-144/Brg1: A potential regulated axis of inflammation in myocardial ischemia-reperfusion injury
- 1 May 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 283, 151
MALAT1/miR-144/Brg1: A potential regulated axis of inflammation in myocardial ischemia-reperfusion injury
- 1 February 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 277, 222
MALAT1/miR-204/LC3-II: A potential regulated axis of autophagy in myocardial ischemia-reperfusion injury
- 1 February 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 277, 222
MALAT1/miR-204/LC3-II: A potential regulated axis of autophagy in myocardial ischemia-reperfusion injury
- 1 October 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 268, 245
LncRNA MALAT1 sponges miR-203 to promote inflammation in myocardial ischemia-reperfusion injury
- 1 October 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 268, 245
LncRNA MALAT1 sponges miR-203 to promote inflammation in myocardial ischemia-reperfusion injury
- Open Access
- 1 January 2017
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 3542149
Inhibition of Caveolae Contributes to Propofol Preconditioning‐Suppressed Microvesicles Release and Cell Injury by Hypoxia‐Reoxygenation
Endothelial microvesicles (EMVs), released after endothelial cell (EC) apoptosis or activation, may carry many adverse signals and propagate injury by intercellular transmission. Caveolae are 50–100 nm cell surface plasma membrane invaginations involved in many pathophysiological processes. Recent evidence has indicated EMVs and caveolae may have functional effects in cells undergoing H/R injury. Propofol, a widely used anaesthetic, confers antioxidative stress capability in the same process. But the connection between EMVs, H/R, and caveolae remains largely unclear. Here, we found that H/R significantly increased the release of EMVs, the expression of CAV‐1 (the structural protein responsible for maintaining the shape of caveolae), oxidative stress, and the mitochondrial damage, and all these changes were inhibited by propofol preconditioning. Interestingly, the caveolae inhibitor Mβ‐CD strengthened the protective effect of propofol preconditioning. We further found that the release of EMVs is more significantly reduced under propofol preconditioning in the presence of the caveolae inhibitor Mβ‐CD. EMVs released from H/R‐treated cells caused a substantially increased mitochondrial and cellular damage to normal HUVECs after 4 hours of coculture. Thus, we conclude that inhibition of caveolae contributes to propofol preconditioning‐suppressed microvesicles release and cell injury by H/R.
- 1 January 2017
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2017 (1) , 3542149
Open AccessInhibition of Caveolae Contributes to Propofol Preconditioning‐Suppressed Microvesicles Release and Cell Injury by Hypoxia‐Reoxygenation
Endothelial microvesicles (EMVs), released after endothelial cell (EC) apoptosis or activation, may carry many adverse signals and propagate injury by intercellular transmission. Caveolae are 50–100 nm cell surface plasma membrane invaginations involved in many pathophysiological processes. Recent evidence has indicated EMVs and caveolae may have functional effects in cells undergoing H/R injury. Propofol, a widely used anaesthetic, confers antioxidative stress capability in the same process. But the connection between EMVs, H/R, and caveolae remains largely unclear. Here, we found that H/R significantly increased the release of EMVs, the expression of CAV‐1 (the structural protein responsible for maintaining the shape of caveolae), oxidative stress, and the mitochondrial damage, and all these changes were inhibited by propofol preconditioning. Interestingly, the caveolae inhibitor Mβ‐CD strengthened the protective effect of propofol preconditioning. We further found that the release of EMVs is more significantly reduced under propofol preconditioning in the presence of the caveolae inhibitor Mβ‐CD. EMVs released from H/R‐treated cells caused a substantially increased mitochondrial and cellular damage to normal HUVECs after 4 hours of coculture. Thus, we conclude that inhibition of caveolae contributes to propofol preconditioning‐suppressed microvesicles release and cell injury by H/R.
- Open Access
- 10 October 2016
- Published by Wiley in BioMed Research International
- Vol. 2016, 1-8
Endothelial Microparticles Act as Novel Diagnostic and Therapeutic Biomarkers of Diabetes and Its Complications: A Literature Review
Diabetes mellitus- (DM-) related vascular diseases attract increased attention due to their high morbidity and mortality. The incidence of obesity, atherosclerosis, coronary heart disease, hypertension, and dyslipidemia is significantly higher in DM patients, with an earlier onset and faster progression compared with non-DM patients. DM-related vascular diseases including macrovascular and microvascular complications are characterized by endothelial dysfunction. Therefore, a better understanding of the etiology and mechanisms of endothelial dysfunction is important for the diagnosis and treatment of DM. Endothelial microparticles (EMPs) are new diagnostic and therapeutic targets and biomarkers in DM-related vascular disease. Circulating EMPs containing biologically active substances act as intercellular signals under physiological and pathological conditions. They serve as biological markers of altered vascular endothelium and reflect the pathological progression and diminished endothelial function of blood vessels. Recent evidence suggests that the plasma level of EMPs is significantly higher in DM patients than in healthy population and is significantly correlated with DM-related complications. These observations have prompted speculation that EMPs play a crucial role in the pathophysiology of DM. This review summarizes the known and potential roles of EMPs in the diagnosis, staging, treatment, and clinical prognosis of DM and related vascular diseases.
- 10 October 2016
- Published by Wiley in BioMed Research International
- Vol. 2016, 1-8
Open AccessEndothelial Microparticles Act as Novel Diagnostic and Therapeutic Biomarkers of Diabetes and Its Complications: A Literature Review
Diabetes mellitus- (DM-) related vascular diseases attract increased attention due to their high morbidity and mortality. The incidence of obesity, atherosclerosis, coronary heart disease, hypertension, and dyslipidemia is significantly higher in DM patients, with an earlier onset and faster progression compared with non-DM patients. DM-related vascular diseases including macrovascular and microvascular complications are characterized by endothelial dysfunction. Therefore, a better understanding of the etiology and mechanisms of endothelial dysfunction is important for the diagnosis and treatment of DM. Endothelial microparticles (EMPs) are new diagnostic and therapeutic targets and biomarkers in DM-related vascular disease. Circulating EMPs containing biologically active substances act as intercellular signals under physiological and pathological conditions. They serve as biological markers of altered vascular endothelium and reflect the pathological progression and diminished endothelial function of blood vessels. Recent evidence suggests that the plasma level of EMPs is significantly higher in DM patients than in healthy population and is significantly correlated with DM-related complications. These observations have prompted speculation that EMPs play a crucial role in the pathophysiology of DM. This review summarizes the known and potential roles of EMPs in the diagnosis, staging, treatment, and clinical prognosis of DM and related vascular diseases.
- 1 February 2007
- Published by Elsevier in Neuroscience Letters
- Vol. 413 (2) , 163-167
ω-Conotoxin MVIIA inhibits amygdaloid kindled seizures in Sprague–Dawley rats
- 1 February 2007
- Published by Elsevier in Neuroscience Letters
- Vol. 413 (2) , 163-167
ω-Conotoxin MVIIA inhibits amygdaloid kindled seizures in Sprague–Dawley rats